Description
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer[1][2].—Cancer-programmed cell death–C49H63F5N12O10—-[1]Dietrich JB, et, al. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells. Regul Pept. 1994 Oct 21;53(3):165-73. |[2]Damgé C, et, al. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86.–136207-23-3–1075.09—-CC(C)C[C@@H](C(OC)=O)NC([C@H](CC1=CNC=N1)NC([C@@H](C)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC2=CNC3=CC=CC=C23)NC([C@H](CCC(N)=O)NC([C@@H](CC4=C(F)C(F)=C(F)C(F)=C4F)N)=O)=O)=O)=O)=O)=O)=O–Cancer–H2O–Bombesin Receptor—-GPCR/G Protein–Peptides
